Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

26. srpna 2026 aktualizováno: Hua Huang, MD, PhD

A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)

The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:

  • Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
  • Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.

Participants will:

  • Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
  • Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
  • If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
  • If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
  • In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
  • In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
  • Complete quality of life questionnaires at predefined time points
  • Be followed up for survival, disease progression, adverse events and medical resource use outcomes

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

170

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína, 100853
        • Chinese PLA General Hospital
        • Kontakt:
      • Beijing, Beijing Municipality, Čína, 102206
        • Peking University International Hospital
        • Kontakt:
      • Beijing, Beijing Municipality, Čína, 100142
        • Peking University Cancer Hospital
        • Kontakt:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Čína, 400038
        • The First Affiliated Hospital of Army Medical University
        • Kontakt:
    • Fujian
      • Zhangzhou, Fujian, Čína, 363000
        • Zhangzhou Affiliated hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Čína, 510060
        • Sun Yat-sen University Cancer Center
        • Kontakt:
      • Guangzhou, Guangdong, Čína, 510515
        • Nanfang Hospital, Southern Medical University
        • Kontakt:
      • Guangzhou, Guangdong, Čína, 510655
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Čína, 430030
        • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
        • Kontakt:
    • Jiangsu
      • Nanjing, Jiangsu, Čína, 210029
        • Jiangsu Province Hospital
        • Kontakt:
      • Nanjing, Jiangsu, Čína, 210009
        • Jiangsu Cancer Hospital
        • Kontakt:
      • Nanjing, Jiangsu, Čína, 210008
        • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
        • Kontakt:
      • Nantong, Jiangsu, Čína, 226001
        • Nantong First People's Hospital
        • Kontakt:
          • shichun feng
          • Telefonní číslo: +86 0513-81111888
          • E-mail: fsc2200@126.com
    • Jiangxi
      • Nanchang, Jiangxi, Čína, 330006
        • The First Affiliated Hospital of Nanchang University
        • Kontakt:
      • Nanchang, Jiangxi, Čína, 330006
        • The Second Affiliated Hospital of Nanchang University
        • Kontakt:
      • Shangrao, Jiangxi, Čína, 334000
        • Shangrao People's Hospital
        • Kontakt:
    • Jilin
      • Changchun, Jilin, Čína, 130021
        • The First Hospital of Jilin University
        • Kontakt:
    • Liaoning
      • Dalian, Liaoning, Čína, 116011
        • The First Affiliated Hospital of Dalian Medical University
        • Kontakt:
    • Shaanxi
      • Xi'an, Shaanxi, Čína, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Kontakt:
      • Xi'an, Shaanxi, Čína, 710038
        • The Second Affiliated Hospital of Airforce Military Medical University
        • Kontakt:
    • Shandong
      • Jinan, Shandong, Čína, 250021
      • Jinan, Shandong, Čína, 250014
        • The First Affiliated Hospital of Shandong First Medical University
        • Kontakt:
      • Qingdao, Shandong, Čína
        • The Affiliated Hospital of Qingdao University
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Čína, 200032
        • Fudan University Shanghai Cancer Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Hua Huang, MD,PHD
      • Shanghai, Shanghai Municipality, Čína
        • Shanghai General Hospital
        • Kontakt:
    • Shanxi
      • Changzhi, Shanxi, Čína, 046000
        • Changzhi People'S Hospital
        • Kontakt:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Čína, 300060
        • Tianjin Medical University Cancer Institute&Hospital
        • Kontakt:
    • Xinjiang
      • Ürümqi, Xinjiang, Čína, 830011
        • Affiliated Cancer Hospital of Xinjiang Medical University
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Čína, 310022
        • Zhejiang Cancer Hospital
        • Kontakt:
      • Hangzhou, Zhejiang, Čína, 310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • Kontakt:
      • Hangzhou, Zhejiang, Čína, 310016
        • Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
  • Age ≥ 18 years and ≤ 70 years.
  • Histologically and/or cytologically confirmed gastric cancer.
  • No evidence of gastric outlet obstruction or intestinal obstruction.
  • No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
  • No prior chemotherapy, targeted therapy, or immunotherapy.
  • ECOG performance status score of 0-2.
  • Life expectancy ≥ 12 weeks.
  • Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

Exclusion Criteria:

  • Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
  • Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
  • Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
  • Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
  • Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
  • Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
  • Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
  • Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
  • Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
  • Any other condition deemed by the investigator as inappropriate for participation in this study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Surgery Group
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy. Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
Aktivní komparátor: Standard Treatment Group
Patients do not undergo surgery. They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal. Salvage surgery is permitted if clinically indicated.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Časové okno
Overall Survival (OS)
Časové okno: Up to 3 years after randomization
Up to 3 years after randomization

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
Časové okno: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
Časové okno: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Pathological Complete Response (pCR) Rate
Časové okno: At the time of radical surgery
At the time of radical surgery
R0 Resection Rate
Časové okno: At the time of radical surgery
At the time of radical surgery
Complication-Free Survival
Časové okno: Up to 3 years after randomization
Up to 3 years after randomization
Major Complication Rate
Časové okno: Within 30 days and 90 days after surgery
Within 30 days and 90 days after surgery
Progression-Free Survival (PFS) and Peritoneal PFS
Časové okno: Up to 3 years after randomization
Up to 3 years after randomization
Time to Peritoneal Re-dissemination
Časové okno: Up to 3 years after randomization
Up to 3 years after randomization
Length of Hospital Stay
Časové okno: Perioperative period
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
Perioperative period
Readmission Rate
Časové okno: Within 30 days and 90 days post-surgery
Within 30 days and 90 days post-surgery
Treatment Interruption Rate
Časové okno: Within 1-year after randomization
Within 1-year after randomization
Direct Medical Costs / Hospitalization Costs
Časové okno: Baseline through study completion, an average of 3-years post-randomization
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications. Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
Baseline through study completion, an average of 3-years post-randomization

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. října 2026

Primární dokončení (Odhadovaný)

1. října 2031

Dokončení studie (Odhadovaný)

1. října 2031

Termíny zápisu do studia

První předloženo

23. srpna 2026

První předloženo, které splnilo kritéria kontroly kvality

26. srpna 2026

První zveřejněno (Aktuální)

27. srpna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

27. srpna 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

26. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Individual-participant-level raw data will not be shared externally. Aggregated study results will be published in peer-reviewed journals.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit